Noaxo (Omeprazole)

Omeprazole, the active ingredient in Noaxo, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is used to manage conditions such as gastro‑oesophageal reflux disease, peptic ulcer disease and related disorders in adult patients.

GNH USA supplies Noaxo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric acid secretion pathway and is indicated for several gastrointestinal conditions. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal irritation. - Peptic ulcer disease: supports ulcer healing by maintaining a less acidic gastric environment. - Erosive esophagitis: reduces acid exposure to allow mucosal recovery. - Helicobacter pylori eradication regimens: used in combination therapy to improve eradication rates.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: usually transient. - Nausea or abdominal discomfort. - Flatulence: occasional. - Constipation: infrequent. - Dry mouth: mild.

Serious or Rare Side Effects: - Severe allergic reactions (e.g., angio‑edema, anaphylaxis). - Clostridioides difficile‑associated diarrhoea. - Low magnesium levels (hypomagnesemia) with prolonged use. - Bone fracture risk with long‑term therapy. - Liver enzyme elevations. - Interstitial nephritis.

When prescribing Omeprazole, consider the following precautions. - Assess renal and hepatic function: adjust monitoring in patients with impairment. - Evaluate for Helicobacter pylori infection: confirm eradication after therapy. - Review long‑term use: limit duration to the shortest effective period. - Monitor for nutrient deficiencies: especially vitamin B12 and magnesium with extended therapy. - Counsel on potential drug interactions: especially with antiplatelet agents and warfarin. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Omeprazole may affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect; consider alternative therapy. - Atazanavir or other protease inhibitors: markedly decreased absorption; avoid co‑administration.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR; monitor coagulation parameters. - Methotrexate (high dose): reduced clearance; check serum levels. - Digoxin: increased serum concentration; observe for toxicity. - Phenytoin: decreased plasma levels; adjust dosage if needed. - Iron supplements: reduced absorption; separate dosing by at least 2 hours.